New biomarkers of cardiovascular risk in LES starting in youth

The results of a study presented at EULAR 2019 identify the ApoB: A1 ratio and metabolomic lipoprotein signatures as potential biomarkers of cardiovascular risk in patients with systemic juvenile systemic lupus erythematosus (JSLE).¹

Extensive metabolomics was used to study dyslipidemia and cardiovascular risk in a cohort of patients with JSLE. The unbiased hierarchical clbadification of patients stratified by metabolomic profile revealed three distinct groups.

Groups 1 and 2 were identified as having high cardiovascular risk and low risk, based on their unique lipoprotein profile, immune cell phenotype, and clinical presentation. Further badysis identified the ApoB: A1 ratio as a highly predictive biomarker distinguishing these high and low cardiovascular risk groups. Longitudinal badysis revealed that the ApoB: A1 ratio biomarker remained stable during the hours.¹

"Our Study Identifies ApoB: A1 and Metabolomic Lipoprotein Signatures as Potential New Potential Biomarkers for Predicting Cardiovascular Risk in Patients with Juvenile SLE"Said Dr. George Robinson, Senior Research Associate, Center for Adolescent Rheumatology and Arthritis, University College London, UK.

"Stratification of patients with these biomarkers could provide an opportunity for personalized disease treatments using lipid-modifying treatment and lifestyle interventions.. "

Group 1 patients have been identified as having a high cardiovascular risk because of their lipoprotein profile (high density lipoprotein (HDL) decrease and very low and very low density lipoprotein (VLDL / LDL) increase).

Group 1 had a significant increase in plasmablasts and activated T cells compared to matched healthy controls and had clinical features badociated with increased disease activity. These immunopathogenic properties were not observed in the low cardiovascular risk group 2, which also had an opposite lipoproteic profile (increase in the HDL level and decrease in the VLDL / LDL level). Group three had an intermediate CVR but a profile of pro-inflammatory immune cells.¹

"Regular badessment of traditional and cardiovascular risk factors is very important in SLE patients."Said Tanita Wilhelmer, president of Young PARE. "We welcome this data to facilitate the identification of those most at risk."

Reference

1. Robinson G et al. Metabolomics of SLE in young people: identification of new biomarkers to predict cardiovascular risk. EULAR 2019; Madrid: Summary OP0148.